Results 11 to 20 of about 1,710,685 (294)

Drugs and Devices

open access: yesJACC: Basic to Translational Science, 2016
The regulation of medical drugs and devices involves competing goals of assuring safety and efficacy while providing rapid movement of innovative therapies through the investigative and regulatory processes as quickly as possible.
Gail A. Van Norman, MD
doaj   +1 more source

Evidence of comparative efficacy should have a formal role in European drug approvals [PDF]

open access: yes, 2011
Despite methodological concerns, comparative efficacy evidence should be required at the time of drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other healthcare decision makers to determine whether a new drug is ...
Cylus, Jonathan   +3 more
core   +2 more sources

Disclosure of Clinical Trial Data: Why Exemption 4 of the Freedom of Information Act Should Be Restored [PDF]

open access: yes, 2005
Clinical trial data generated during the FDA drug approval process can be very valuable. While patients and doctors desperately need this information to make informed choices about medical treatment, drug sponsors strive to keep this resource secret to ...
Boyce, Janene
core   +3 more sources

Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America

open access: yesRevista Panamericana de Salud Pública, 2022
Objectives. To map the timing and nature of regulatory reliance pathways used to authorize COVID-19 vaccines in Latin America. Methods. An observational study was conducted assessing the characteristics of all COVID-19 vaccine authorizations in Latin ...
Ivar T. van der Zee   +3 more
doaj   +1 more source

Pharmacists’ Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation

open access: yesPharmacy, 2022
The “breakthrough therapy” designation (BTD) is a recent mechanism implemented by the United States Food and Drug Administration (FDA) to expedite access to drugs that address unmet needs.
Megan C. Herink   +4 more
doaj   +1 more source

Product Complexity and Strategic Alliance on Drug Approval

open access: yesAmerican Business Review, 2021
Management of the business-government relationship is critical for firm performance in regulated industries. In this paper, we predict a U-shaped relationship between product complexity and the time to approval by the US Food and Drug Administration (FDA)
Taoyong Su   +3 more
doaj   +1 more source

Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study

open access: yesJournal of Pharmaceutical Policy and Practice, 2017
Background The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but usually focuses on diseases common in those ...
Rumiko Shimazawa, Masayuki Ikeda
doaj   +1 more source

Drugs, Devices, and the FDA: Part 1

open access: yesJACC: Basic to Translational Science, 2016
Over the last 150 years, the U.S. Food and Drug Administration (FDA) has evolved from a small division of the U.S. Patent Office to 1 of the largest consumer protection agencies in the world.
Gail A. Van Norman, MD
doaj   +1 more source

Pragmatic clinical trials in the context of regulation of medicines

open access: yesUpsala Journal of Medical Sciences, 2019
The pragmatic clinical trial addresses scientific questions in a setting close to routine clinical practice and sometimes using routinely collected data.
Rolf Gedeborg   +3 more
doaj   +1 more source

Adapting drug approval pathways for bacteriophage-based therapeutics

open access: yesFrontiers in Microbiology, 2016
The global rise of multi-drug resistant bacteria has resulted in the notion that an antibiotic apocalypse is fast approaching. This has led to a number of well publicized calls for global funding initiatives to develop new antibacterial agents. The long
Callum Cooper   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy